Top news of the week: 28.02.2023.
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413)...
Biotech downturn hurts companies targeting autism-linked conditions
After a year of intense growth, funding for biotech is in decline. The result is layoffs and program cuts — and maybe some innovation.
Transcend Therapeutics, a mental health-focused biotechnology company, announces Series A funding round of $40 million led by Alpha Wave Global and Integrated Investment Partners
/PRNewswire/ -- Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress...
‘A slippery slope’: A looming nationwide abortion pill ban could undermine the entire drug approval system
“You want the court to decide what drugs are safe and effective? Well, good luck to all of us," said Marc Scheineson, a health care lawyer at Alston & Bird and a former FDA associate ...
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Here's why it makes sense that stocks are rallying as rates rise and a recession approaches, and what to own because they could keep going, according to research firm Leuthold Group.
There are solid reasons for the 'irrational' moves in stocks in 2023, and Doug Ramsey of Leuthold Group says they could keep the recent rally going.
Trump’s 2024 GOP Competition: Investment Firm Manager Vivek Ramaswamy Announces Run For President
Florida Gov. Ron DeSantis, who is polling neck and neck with former President Donald Trump in a hypothetical matchup, is expected to announce his bid for the presidency sometime this summer.
Is China’s attitude to genetically modified crops changing?
A loosening of restrictions may be in the offing